TSW
EBS icon

Thompson Siegel & Walmsley’s Emergent Biosolutions EBS Stock Holding History

Thompson Siegel & Walmsley’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,000
Closed -$202K – 767
2018
Q2 		$202K Buy
+4,000
New +$208K ﹤0.01% 414

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Thompson Siegel & Walmsley's EBS Position: Q3 2018 in Review

Thompson Siegel & Walmsley sold out of Emergent Biosolutions (EBS) in Q3 2018, closing a stake of 4,000 shares — an estimated $202K sold.

Thompson Siegel & Walmsley first reported a position in EBS in Q2 2018 and held it in 1 quarter. The position peaked at $202K in Q2 2018. 275 funds tracked by Wall St. Rank hold EBS as of Q3 2018.

  • Thompson Siegel & Walmsley reported no remaining Emergent Biosolutions position as of Q3 2018 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 4,000 Emergent Biosolutions shares in Q3 2018, an estimated $202K.
  • Thompson Siegel & Walmsley first reported a position in Emergent Biosolutions in Q2 2018 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Emergent Biosolutions position peaked at $202K in Q2 2018.
  • 275 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2018.

Based on Thompson Siegel & Walmsley's 13F filing for Q3 2018, filed 8 Nov 2018.